Chemotherapy Strategies in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Eileen O’Reilly, MD
Efrat Dotan, MD
HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)
Fernando López-Ríos, MD, PhD
Christian Rolfo, MD, PhD
Charlie Gourley, MD, PhD
Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
Fortunato Ciardiello, MD, PhD
Jenny Seligmann, MBChB, PhD
Case Consult: Adverse Effect Monitoring, Management, and Mitigation During Targeted Therapy for BRAF-Mutant mCRC
Patient Perspectives on Bladder Cancer
Elizabeth R. Plimack, MD, MS, FASCO
Lillibeth Velasco, MSN, RN
Reviewing the Latest Bladder Cancer Practice Guidelines
Advancing TROP-2-Targeted ADCs in HR+ Breast Cancer: Navigating Today and Shaping Tomorrow
Javier Cortes, MD, PhD
Hope S. Rugo, MD, FASCO
Metastatic Pancreatic Ductal Adenocarcinoma (PDAC): From Diagnosis to Treatment
Shubham Pant, MD, MBBS
Diagnosis and Management of Metastatic PDAC
Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence
Sara Lonardi, MD
Innovations in Oncology Learning Center From Guidelines to Practice: Gastrointestinal Cancers
Aparna R. Parikh, MD
Alan Venook, MD
Immunotherapy-Based Approaches for First-Line Treatment of Advanced HCC: The Evidence
Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations
Peter Schmid, FRCP, MD, PhD
Expert Viewpoint: Optimizing Breast Cancer Treatment
William J. Gradishar, MD
Erica L. Mayer, MD, MPH
First-Line Advanced Gastric Cancer: Best Practices for Biomarker-Directed Treatment Approaches—A Case Study
Emerging Treatment Approaches for EBC
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.